AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18697865 — intervention group
Group type: COMPARATOR
Intervention: No E2
Number of subjects: 20
Study 18697865 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot iv bolus ghrelin infusions
Number of subjects: 20
Study 16949487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac stress-testing (n = 386)
Number of subjects: 770
Study 16949487 — intervention group
Group type: COMPARATOR
Intervention: No testing (n = 384)
Number of subjects: 770
Study 16949487 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (testing and no testing) with HR <65 beats/min
Number of subjects: 770
Study 16949487 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (testing and no testing) with HR >=65 beats/min
Number of subjects: 770
Study 14556812 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate 20 mg/d and testosterone undecanoate 120 mg/d (n = 106)
Number of subjects: 212
Study 14556812 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n = 106)
Number of subjects: 212
Study 14556812 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group (n = 106)
Number of subjects: 212
Study 14556812 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 106)
Number of subjects: 212
Study 10972169 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal pouch reconstruction
Number of subjects: 34
Study 10972169 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y reconstruction
Number of subjects: 34
Study 8958461 — intervention group
Group type: EXPERIMENTAL
Intervention: Allegation informed interview technique (196 interviews)
Number of subjects: 1535
Study 8958461 — intervention group
Group type: COMPARATOR
Intervention: Allegation blind interview technique (1,330 interviews)
Number of subjects: 1535
Study 1526694 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone therapy
Number of subjects: 18
Study 3966649 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of 0.3 molar sodium citrate less than 60 min preoperatively (n = 11)
Number of subjects: 32
Study 3966649 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of 0.3 molar sodium citrate longer than 60 min preoperatively (n = 11)
Number of subjects: 32
Study 3966649 — intervention group
Group type: COMPARATOR
Intervention: No antacid (control group, n = 10)
Number of subjects: 32
Study 30346822 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuderm (single-use tourniquet with manual vacuum pump)
Number of subjects: 20
Study 30346822 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (without Vacuderm)
Number of subjects: 20
Study 27183035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (2 times per week for 12 weeks)
Number of subjects: 204
Study 27183035 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (2 times per week for 6 weeks, followed by 6 weeks of monitored home exercise)
Number of subjects: 204
Study 27183035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 204
Study 27183035 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 204
Study 25305179 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 34
Study 22492374 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T TT genotype
Number of subjects: 5925
Study 20388073 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (HA) injection
Number of subjects: 0
Study 18063205 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg
Number of subjects: 90
Study 18063205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 90
Study 18063205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 16303721 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcapsular orchiectomy
Number of subjects: 86
Study 16303721 — intervention group
Group type: COMPARATOR
Intervention: Total orchiectomy
Number of subjects: 86
Study 11994042 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus best supportive care
Number of subjects: 0
Study 11994042 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin
Number of subjects: 0
Study 9466504 — intervention group
Group type: EXPERIMENTAL
Intervention: Conductivity method
Number of subjects: 31
Study 9466504 — intervention group
Group type: COMPARATOR
Intervention: Low-flow technique
Number of subjects: 31
Study 7610459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefteram-pivoxil (CFTM-PI)
Number of subjects: 0
Study 2673130 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 60
Study 2673130 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 60
Study 2673130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 5443056 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic vaginal ring impregnated with medroxyprogesterone acetate
Number of subjects: 3
Study 5443056 — intervention group
Group type: COMPARATOR
Intervention: Silastic vaginal ring without medication (Control)
Number of subjects: 3
Study 30985624 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid treatment (n=58, 10-16 sessions)
Number of subjects: 115
Study 30985624 — intervention group
Group type: COMPARATOR
Intervention: iCBT (n=57; 8 treatment modules)
Number of subjects: 115
Study 28668073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Number of subjects: 1644
Study 28668073 — intervention group
Group type: COMPARATOR
Intervention: No sentinel lymph node biopsy
Number of subjects: 1644
Study 26015389 — intervention group
Group type: EXPERIMENTAL
Intervention: Eggs rich in C18:3 ω‐3, eicosapentaenoic acid (EPA, 20:5 ω‐3) and docosahexaenoic acid (DHA, 22:6 ω‐3) for 3 months
Number of subjects: 179
Study 26015389 — intervention group
Group type: COMPARATOR
Intervention: Ordinary eggs (control group)
Number of subjects: 179
Study 26015389 — intervention group
Group type: EXPERIMENTAL
Intervention: Eggs rich in ω‐3 PUFAs
Number of subjects: 179
Study 23736523 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-based pursuit
Number of subjects: 0
Study 23736523 — intervention group
Group type: EXPERIMENTAL
Intervention: Popping out of the correct spot to enhance retinal image-motion inputs
Number of subjects: 0
Study 23736523 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial blanking of spot motion during memory-based pursuit
Number of subjects: 0
Study 21355444 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of pioglitazone 45 mg
Number of subjects: 0
Study 21355444 — intervention group
Group type: COMPARATOR
Intervention: Reference product of pioglitazone 45 mg
Number of subjects: 0
Study 21355444 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncated AUCs
Number of subjects: 0
Study 19954060 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA expression of functional genes of neutrophils, monophagocytes, IFN regulating factors, TNF, adhesion molecules and T cells in PE patients
Number of subjects: 0
Study 19954060 — intervention group
Group type: COMPARATOR
Intervention: mRNA expression of B cell immune function and complement activation associated factors in PE patients
Number of subjects: 0
Study 17000504 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 54
Study 17000504 — intervention group
Group type: COMPARATOR
Intervention: Gemeprost
Number of subjects: 54
Study 15543397 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral catheter removal after 7 days (Group 1)
Number of subjects: 73
Study 15543397 — intervention group
Group type: COMPARATOR
Intervention: Urethral catheter removal after 14 days (Group 2)
Number of subjects: 73
Study 15543397 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (7 days and 14 days)
Number of subjects: 73
Study 10834777 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 8 mg + Fentanyl 10 microg
Number of subjects: 120
Study 10834777 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 10 mg + Fentanyl 10 microg
Number of subjects: 120
Study 10834777 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 12 mg
Number of subjects: 120
Study 10834777 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 12 mg + Fentanyl 10 microg
Number of subjects: 120
Study 9105817 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm cardioplegia
Number of subjects: 1374
Study 9105817 — intervention group
Group type: COMPARATOR
Intervention: Cold cardioplegia
Number of subjects: 1374
Study 9105817 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm cardioplegia (low risk)
Number of subjects: 1374
Study 9105817 — intervention group
Group type: COMPARATOR
Intervention: Cold cardioplegia (low risk)
Number of subjects: 1374
Study 9105817 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm cardioplegia (high risk)
Number of subjects: 1374
Study 9105817 — intervention group
Group type: COMPARATOR
Intervention: Cold cardioplegia (high risk)
Number of subjects: 1374
Study 7681510 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine after 1 week of oral ramipril
Number of subjects: 12
Study 7681510 — intervention group
Group type: COMPARATOR
Intervention: Felodipine after placebo
Number of subjects: 12
Study 7681510 — intervention group
Group type: COMPARATOR
Intervention: Solvent after ramipril
Number of subjects: 12
Study 3092654 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms intragastrically
Number of subjects: 6
Study 3092654 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms intragastrically
Number of subjects: 6
Study 3092654 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms intraduodenally
Number of subjects: 6
Study 3092654 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms intraduodenally
Number of subjects: 6
Study 3092654 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg intragastrically
Number of subjects: 6
Study 3092654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31721089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon capsules for 60 days
Number of subjects: 0
Study 31721089 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat twice daily for 30 days, then once daily for another 30 days
Number of subjects: 0
Study 30194826 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (online course during the first internship)
Number of subjects: 36
Study 30194826 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (online course during the second internship)
Number of subjects: 36
Study 26201085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab treatment
Number of subjects: 20
Study 23389863 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - exercise class including pelvic floor muscle training (PFMT)
Number of subjects: 169
Study 23389863 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - usual care
Number of subjects: 169
Study 22246115 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Number of subjects: 1272
Study 20225994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebicapone 100 mg
Number of subjects: 18
Study 20225994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebicapone 200 mg
Number of subjects: 18
Study 20225994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 18404296 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative decolonization protocol using mupirocin ointment (twice daily) and chlorhexidine bath (once daily) for 5 days before surgery.
Number of subjects: 636
Study 18404296 — intervention group
Group type: COMPARATOR
Intervention: Concurrent control group (patients of surgeons who did not participate in the intervention study).
Number of subjects: 636
Study 18404296 — intervention group
Group type: COMPARATOR
Intervention: Preintervention control group (patients of participating surgeons who had undergone elective TJA during the year before the study).
Number of subjects: 636
Study 15811057 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX 0.2%+alcohol (Corsodyl)
Number of subjects: 48
Study 15811057 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX 0.05%+CPC 0.05% (Perio‐Aid Maintenance)
Number of subjects: 48
Study 15811057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11922549 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg)
Number of subjects: 5241
Study 11922549 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg)
Number of subjects: 5241
Study 10755770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dietary advice
Number of subjects: 200
Study 10755770 — intervention group
Group type: COMPARATOR
Intervention: Routine dietary advice (Control)
Number of subjects: 200
Study 10755770 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 7857114 — intervention group
Group type: EXPERIMENTAL
Intervention: Jessner's solution and 35% trichloroacetic acid (single application)
Number of subjects: 15
Study 7857114 — intervention group
Group type: COMPARATOR
Intervention: 5% fluorouracil cream (twice daily applications for 3 weeks)
Number of subjects: 15
Study 2023750 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-507 given every 8 or 12 hours for 4 days
Number of subjects: 82
Study 2023750 — intervention group
Group type: EXPERIMENTAL
Intervention: sezolamide given every 8 hours for 4 days
Number of subjects: 82
Study 2023750 — intervention group
Group type: COMPARATOR
Intervention: Placebo given every 8 or 12 hours for 4 days
Number of subjects: 82
Study 7112797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin macrocrystals 200 mg daily
Number of subjects: 3
Study 7112797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 31270902 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 42
Study 31270902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite
Number of subjects: 42
Study 31270902 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 42
Study 31270902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 42
Study 30066248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-RADS categorization by seven observers
Number of subjects: 3360
Study 30066248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-RADS categorization
Number of subjects: 3360
Study 27859478 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Chewing Training (FuCT)
Number of subjects: 80
Study 27859478 — intervention group
Group type: COMPARATOR
Intervention: Traditional oral motor exercises (Control)
Number of subjects: 80
Study 26255012 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin sodium (LMWHS) 2,500 U subcutaneously, twice a day for 5 days
Number of subjects: 36
Study 26255012 — intervention group
Group type: COMPARATOR
Intervention: Heparin sodium 12,500 U intravenously for 24 hours for 5 days
Number of subjects: 36
Study 23140479 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked Gabor patches presented in the fovea
Number of subjects: 0
Study 23140479 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked Gabor patches presented in near periphery (6°)
Number of subjects: 0
Study 23140479 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked and randomized procedures
Number of subjects: 0
Study 21779669 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin tissue adhesive (Quixil™)
Number of subjects: 47
Study 21779669 — intervention group
Group type: COMPARATOR
Intervention: Mononylon 10‐0 suture (Ethicon(®))
Number of subjects: 47
Study 19375808 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward-planned IMRT
Number of subjects: 1145
Study 19375808 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy
Number of subjects: 1145
Study 16489947 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth root planing (FMRP)
Number of subjects: 20
Study 16489947 — intervention group
Group type: COMPARATOR
Intervention: Quadrant root planing (QRP)
Number of subjects: 20
Study 15545163 — intervention group
Group type: EXPERIMENTAL
Intervention: OMC (ome 20 mg b.i.d., metronidazole 400 mg b.i.d., clarithromycin 250 mg b.i.d.)
Number of subjects: 125
Study 15545163 — intervention group
Group type: COMPARATOR
Intervention: OP (ome 20 mg and placebo)
Number of subjects: 125
Study 15545163 — intervention group
Group type: EXPERIMENTAL
Intervention: OMC (ome 20 mg b.i.d., metronidazole 400 mg b.i.d., clarithromycin 250 mg b.i.d.) with NSAIDs
Number of subjects: 125
Study 15545163 — intervention group
Group type: COMPARATOR
Intervention: OP (ome 20 mg and placebo) with NSAIDs
Number of subjects: 125
Study 15545163 — intervention group
Group type: EXPERIMENTAL
Intervention: OMC
Number of subjects: 125
Study 15545163 — intervention group
Group type: COMPARATOR
Intervention: OP
Number of subjects: 125
Study 12577391 — intervention group
Group type: EXPERIMENTAL
Intervention: Acanthopanax senticosus (AS) treatment
Number of subjects: 47
Study 12577391 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 47
Study 9029427 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude-modulated light exposure
Number of subjects: 20
Study 9029427 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy volunteers)
Number of subjects: 20
Study 8400346 — intervention group
Group type: EXPERIMENTAL
Intervention: octreotide 0.5 mg three times per day s.c.
Number of subjects: 40
Study 8400346 — intervention group
Group type: COMPARATOR
Intervention: loperamide 4 mg three times per day p.o.
Number of subjects: 40
Study 2439781 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bisoprolol
Number of subjects: 45
Study 2439781 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 45
Study 2439781 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg bisoprolol
Number of subjects: 45
Study 2439781 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after discontinuation of active treatment)
Number of subjects: 45
Study 2439781 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of bisoprolol (5, 10, 20 mg)
Number of subjects: 45
Study 2439781 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of bisoprolol
Number of subjects: 45
Study 29540325 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors (SGLT-2i)
Number of subjects: 235064
Study 27028341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg daily for 6 months
Number of subjects: 32
Study 27028341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 24682973 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 24
Study 21169260 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (Cyclophosphamide, intravenous doxorubicin, and 5-fluorouracil)
Number of subjects: 458
Study 21169260 — intervention group
Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide, intravenous methotrexate, and 5-fluorouracil) ± tamoxifen
Number of subjects: 458
Study 21169260 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (874 women with presumed favorable prognosis)
Number of subjects: 458
Study 18164451 — intervention group
Group type: EXPERIMENTAL
Intervention: Back schools
Number of subjects: 0
Study 18164451 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief education
Number of subjects: 0
Study 18164451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-avoidance training
Number of subjects: 0
Study 16200760 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted combinations of sensorimotor rhythm amplitudes using a regression algorithm based on past performance
Number of subjects: 0
Study 16200760 — intervention group
Group type: COMPARATOR
Intervention: Single feature control of cursor movement
Number of subjects: 0
Study 16200760 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression algorithm for cursor control
Number of subjects: 0
Study 12690224 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg/kg plus ethanol 0.2 g/kg
Number of subjects: 23
Study 12690224 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 8 mg/kg plus ethanol 0.4 g/kg
Number of subjects: 23
Study 12690224 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinol (caffeine and ethanol)
Number of subjects: 23
Study 12690224 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant thrombolytic therapy
Number of subjects: 23
Study 12690224 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and ethanol
Number of subjects: 23
Study 10663449 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg intravenous glibenclamide (Gb)
Number of subjects: 20
Study 10663449 — intervention group
Group type: COMPARATOR
Intervention: No glibenclamide (control)
Number of subjects: 20
Study 8860761 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative transfusion (packed red blood cells)
Number of subjects: 269
Study 8860761 — intervention group
Group type: COMPARATOR
Intervention: No transfusion
Number of subjects: 269
Study 1531219 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g/m2 of etanidazole administered intravenously after 30 min (group A)
Number of subjects: 34
Study 1531219 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g/m2 of etanidazole administered intravenously after 60 min (group B)
Number of subjects: 34
Study 1531219 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g/m2 of etanidazole administered intravenously after 120 min (group C)
Number of subjects: 34
Study 1531219 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanidazole associated with radiotherapy
Number of subjects: 34
Study 1531219 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanidazole determination carried out with a polarographic method
Number of subjects: 34
Study 6510061 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational daycare
Number of subjects: 0
Study 6510061 — intervention group
Group type: COMPARATOR
Intervention: No educational intervention
Number of subjects: 0
Study 30500267 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐REHAB
Number of subjects: 89
Study 30500267 — intervention group
Group type: COMPARATOR
Intervention: STAND
Number of subjects: 89
Study 27839981 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 30 U/kg
Number of subjects: 15
Study 27839981 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 60 U/kg
Number of subjects: 15